BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 27644663)

  • 1. Value of FDG PET/Contrast-Enhanced CT in Initial Staging of Colorectal Cancer - Comparison with Contrast-Enhanced CT.
    Kunawudhi A; Sereeborwornthanasak K; Promteangtrong C; Siripongpreeda B; Vanprom S; Chotipanich C
    Asian Pac J Cancer Prev; 2016; 17(8):4071-5. PubMed ID: 27644663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated FDG-PET/CT compared with intravenous contrast-enhanced CT for evaluation of metastatic regional lymph nodes in patients with resectable early stage esophageal cancer.
    Okada M; Murakami T; Kumano S; Kuwabara M; Shimono T; Hosono M; Shiozaki H
    Ann Nucl Med; 2009 Jan; 23(1):73-80. PubMed ID: 19205841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative nodal staging of uterine cancer: is contrast-enhanced PET/CT more accurate than non-enhanced PET/CT or enhanced CT alone?
    Kitajima K; Suzuki K; Senda M; Kita M; Nakamoto Y; Sakamoto S; Onishi Y; Maeda T; Yoshikawa T; Ohno Y; Suganuma N; Sugimura K
    Ann Nucl Med; 2011 Aug; 25(7):511-9. PubMed ID: 21670955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of fusion of PET and MRI for staging of endometrial cancer: comparison with ¹⁸F-FDG contrast-enhanced PET/CT and dynamic contrast-enhanced pelvic MRI.
    Kitajima K; Suenaga Y; Ueno Y; Kanda T; Maeda T; Takahashi S; Ebina Y; Miyahara Y; Yamada H; Sugimura K
    Eur J Radiol; 2013 Oct; 82(10):1672-6. PubMed ID: 23727380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
    van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
    J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical value of ⁶⁸Ga-DOTATATE-PET/CT compared to stand-alone contrast enhanced CT for the detection of extra-hepatic metastases in patients with neuroendocrine tumours (NET).
    Albanus DR; Apitzsch J; Erdem Z; Erdem O; Verburg FA; Behrendt FF; Mottaghy FM; Heinzel A
    Eur J Radiol; 2015 Oct; 84(10):1866-72. PubMed ID: 26152870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Added value of pretreatment (18)F-FDG PET/CT for staging of advanced gastric cancer: Comparison with contrast-enhanced MDCT.
    Kawanaka Y; Kitajima K; Fukushima K; Mouri M; Doi H; Oshima T; Niwa H; Kaibe N; Sasako M; Tomita T; Miwa H; Hirota S
    Eur J Radiol; 2016 May; 85(5):989-95. PubMed ID: 27130061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated 18F-FDG PET/CT for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma: comparison with ultrasound and contrast-enhanced CT.
    Jeong HS; Baek CH; Son YI; Choi JY; Kim HJ; Ko YH; Chung JH; Baek HJ
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):402-7. PubMed ID: 16918964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of PET/CT for preoperative staging of advanced gastric cancer: comparison with contrast-enhanced CT.
    Kim EY; Lee WJ; Choi D; Lee SJ; Choi JY; Kim BT; Kim HS
    Eur J Radiol; 2011 Aug; 79(2):183-8. PubMed ID: 20226612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of FDG PET/ceCT in the evaluation of patients with lung cancer.
    Nanni C; Rossetti V; Zompatori M; Ambrosini V; Montesi V; Mascherini D; Pettinato C; Marzola MC; Colletti PM; Rubello D; Fanti S
    Biomed Pharmacother; 2014 Mar; 68(2):219-23. PubMed ID: 24486108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorodeoxyglucose-positron emission tomography/computed tomography performs better than contrast-enhanced computed tomography for metastasis evaluation in the initial staging of pancreatic adenocarcinoma.
    Santhosh S; Mittal BR; Bhasin DK; Rana SS; Gupta R; Das A; Nada R
    Ann Nucl Med; 2017 Oct; 31(8):575-581. PubMed ID: 28689356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
    Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.
    Brush J; Boyd K; Chappell F; Crawford F; Dozier M; Fenwick E; Glanville J; McIntosh H; Renehan A; Weller D; Dunlop M
    Health Technol Assess; 2011 Sep; 15(35):1-192, iii-iv. PubMed ID: 21958472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [18F]Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) in Suspected Recurrent Breast Cancer: A Prospective Comparative Study of Dual-Time-Point FDG-PET/CT, Contrast-Enhanced CT, and Bone Scintigraphy.
    Hildebrandt MG; Gerke O; Baun C; Falch K; Hansen JA; Farahani ZA; Petersen H; Larsen LB; Duvnjak S; Buskevica I; Bektas S; Søe K; Jylling AM; Ewertz M; Alavi A; Høilund-Carlsen PF
    J Clin Oncol; 2016 Jun; 34(16):1889-97. PubMed ID: 27001573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-modality PET/CT and contrast-enhanced CT imaging for pancreatic cancer.
    Zhang J; Zuo CJ; Jia NY; Wang JH; Hu SP; Yu ZF; Zheng Y; Zhang AY; Feng XY
    World J Gastroenterol; 2015 Mar; 21(10):2988-96. PubMed ID: 25780297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Staging pathways in recurrent colorectal carcinoma: is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice?
    Soyka JD; Veit-Haibach P; Strobel K; Breitenstein S; Tschopp A; Mende KA; Lago MP; Hany TF
    J Nucl Med; 2008 Mar; 49(3):354-61. PubMed ID: 18287263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of (11)C-choline PET/CT and enhanced CT in the evaluation of patients with pulmonary abnormalities and locoregional lymph node involvement in lung cancer.
    Peng Z; Liu Q; Li M; Han M; Yao S; Liu Q
    Clin Lung Cancer; 2012 Jul; 13(4):312-20. PubMed ID: 22182444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
    Ergul N; Kadioglu H; Yildiz S; Yucel SB; Gucin Z; Erdogan EB; Aydin M; Muslumanoglu M
    Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?
    Selzner M; Hany TF; Wildbrett P; McCormack L; Kadry Z; Clavien PA
    Ann Surg; 2004 Dec; 240(6):1027-34; discussion 1035-6. PubMed ID: 15570208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.